These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37996622)

  • 1. Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study.
    Sazuka T; Matsushita Y; Sato H; Osawa T; Hinata N; Hatakeyama S; Numakura K; Ueda K; Kimura T; Takahashi M; Tanaka H; Kawasaki Y; Kurahashi T; Kato T; Fujita K; Miyake M; Kojima T; Kitamura H; Miyake H; Ichikawa T
    Sci Rep; 2023 Nov; 13(1):20629. PubMed ID: 37996622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma.
    Hamamoto S; Tasaki Y; Morikawa T; Naiki T; Etani T; Taguchi K; Iwatsuki S; Unno R; Takeda T; Nagai T; Kawase K; Mimura Y; Sugiyama Y; Okada A; Furukawa-Hibi Y; Yasui T
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38929893
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
    Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
    Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
    Santoni M; Massari F; Myint ZW; Iacovelli R; Pichler M; Basso U; Kopecky J; Kucharz J; Buti S; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Bassanelli M; Merler S; Messina C; Küronya Z; Mosca A; Bhuva D; Vau N; Incorvaia L; Rebuzzi SE; Roviello G; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Montironi R; Battelli N; Porta C
    Target Oncol; 2023 Jul; 18(4):559-570. PubMed ID: 37369815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma.
    Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Hashimoto Y; Kondo T; Takagi T
    Jpn J Clin Oncol; 2023 Oct; 53(10):977-983. PubMed ID: 37519060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
    Santini D; Stellato M; De Giorgi U; Pantano F; De Lisi D; Casadei C; Maruzzo M; Bimbatti D; Naglieri E; Buti S; Bersanelli M; De Vivo R; Di Lorenzo G; Sbrana A; Verzoni E; Soraru' M; Fornarini G; Mucciarini C; Grillone F; Mini E; Vignani F; Attademo L; Pignata S; Procopio G
    Am J Clin Oncol; 2021 Mar; 44(3):121-125. PubMed ID: 33617179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Loo Gan C; Huang J; Pan E; Xie W; Schmidt AL; Labaki C; Meza L; Bouchard G; Li H; Jackson-Spence F; Sánchez-Ruiz C; Powles T; Kumar SA; Weise N; Hall WA; Rose BS; Beuselinck B; Suarez C; Pal SK; Choueiri TK; Heng DYC; McKay RR
    Eur Urol Oncol; 2023 Apr; 6(2):204-211. PubMed ID: 36328934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Survival of Real-world Japanese Patients With Advanced Renal Cell Carcinoma Treated With Immuno-oncology Combination Therapy.
    Ueda K; Suekane S; Kurose H; Ito N; Ogasawara N; Hiroshige T; Chikui K; Ejima K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
    Anticancer Res; 2022 Sep; 42(9):4573-4580. PubMed ID: 36039432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
    Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J
    World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
    Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes.
    Venugopal B; Pillai M; Powles T; Savage P; Michael A; Fife K; Klair B; Perrot V; Szabados B
    Clin Genitourin Cancer; 2022 Feb; 20(1):94-94.e10. PubMed ID: 34802966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis.
    Wenzel M; Deuker M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Becker A; Roos FC; Chun FKH; Karakiewicz PI
    Eur J Cancer; 2021 Sep; 155():245-255. PubMed ID: 34392067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
    Martínez Chanzá N; Xie W; Asim Bilen M; Dzimitrowicz H; Burkart J; Geynisman DM; Balakrishnan A; Bowman IA; Jain R; Stadler W; Zakharia Y; Narayan V; Beuselinck B; McKay RR; Tripathi A; Pachynski R; Hahn AW; Hsu J; Shah SA; Lam ET; Rose TL; Mega AE; Vogelzang N; Harrison MR; Mortazavi A; Plimack ER; Vaishampayan U; Hammers H; George S; Haas N; Agarwal N; Pal SK; Srinivas S; Carneiro BA; Heng DYC; Bosse D; Choueiri TK; Harshman LC
    Lancet Oncol; 2019 Apr; 20(4):581-590. PubMed ID: 30827746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
    Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world data on IO-based therapy for metastatic renal cell carcinoma.
    Stühler V; Herrmann L; Rausch S; Stenzl A; Bedke J
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3249-3258. PubMed ID: 35907009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
    Nakaigawa N; Tomita Y; Tamada S; Tatsugami K; Osawa T; Oya M; Kanayama H; Miura Y; Sassa N; Nishimura K; Nozawa M; Masumori N; Miyoshi Y; Kuroda S; Kimura A
    Int J Clin Oncol; 2023 Mar; 28(3):416-426. PubMed ID: 36595123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients.
    Tomita Y; Tatsugami K; Nakaigawa N; Osawa T; Oya M; Kanayama H; Nakayama Kondoh C; Sassa N; Nishimura K; Nozawa M; Masumori N; Miyoshi Y; Kuroda S; Tanaka S; Kimura A; Tamada S
    Int J Urol; 2020 Nov; 27(11):952-959. PubMed ID: 32789967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).
    Kucharz J; Dumnicka P; Kusnierz-Cabala B; Demkow T; Wiechno P
    Med Oncol; 2019 Jan; 36(2):19. PubMed ID: 30666498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.
    Cao X; Tang D; Ratto B; Poole A; Ravichandran S; Jin L; Gao W; Swallow E; Vogelzang NJ
    Clin Genitourin Cancer; 2020 Feb; 18(1):e37-e45. PubMed ID: 31727510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.